Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

doi:10.1056/nejmc1410239

Cited by 96 publications

(36 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, overall patient survival was only improved by 2 to 5 months with these inhibitors. 20 Therefore, it is urgently needed to identify new targets and develop novel approaches for treatment of CRPC patients. Toward that end, we first found that Plk1 level was correlated to PCa cell growth rate and androgen-independent PCa cells were more sensitive to Plk1 inhibition than androgen-dependent PCa cells (Fig.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer

Zhang

Chen

Wang³

et al. 2015

Cell Cycle

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer

Zhang

Chen

Wang³

et al. 2015

Cell Cycle

View full text Add to dashboard Cite

“…All seven studies provided data on survival with follow-up period up to 36 months [29, 31–36]. Analyses of OS were performed in 5,936 patients, with 737 patients for sipuleucel-T (intervention group versus placebo group: 488 versus 249 patients) and 5,199 patients for AR-directed therapies (intervention group versus placebo group: 3,015 versus 2,184 patients).…”

Section: Resultsmentioning

confidence: 99%

“…Seven studies with a total of 5,936 patients reported reduction of PSA level ≥50% as study outcome [29, 31–36], including 689 patients for sipuleucel-T (intervention group versus placebo group: 458 versus 231 patients) and 4,975 patients for AR-directed therapies (intervention group versus placebo group: 2,928 versus 2,047 patients). Pooled RR showed that sipuleucel-T has no significant effect on reducing PSA level ≥50% (RR: 2.51; 95% CI: 0.65–9.73; Z = 1.33; p = 0.18).…”

Section: Resultsmentioning

confidence: 99%

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

Chen

Duan

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR-directed therapies in patients with CRPC. RevMan 5.1 was used for pooled analysis and analysis of publication bias. Seven studies were included in the meta-analysis, with three studies in sipuleucel-T (totally 737 patients, 488 patients in treatment group, and 249 patients in placebo group) and four in AR-directed therapies (totally 5,199 patients, 3,015 patients in treatment group, and 2,184 patients in placebo group). Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p > 0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p > 0.05).

show abstract

“…Nevertheless, disease progression still occurs (castration-resistant prostate cancer), although there is evidence that in this case cancer progression continues to be driven by androgen signaling 11 . To reinforce the suppression of AR signaling, several AR antagonists have been developed.…”

Section: Discussionmentioning

confidence: 99%

“…Prostate cancer therapy heavily relies on androgen deprivation which has improved survival 11 . Nevertheless, disease progression still occurs (castration-resistant prostate cancer), although there is evidence that in this case cancer progression continues to be driven by androgen signaling 11 .…”

Section: Discussionmentioning

confidence: 99%

Radiopotentiation of Enzalutamide Over Human Prostate Cancer Cells as Assessed by Real-Time Cell Monitoring

Barrado¹,

Blanco‐Luquin²,

Andrea-Navarrete³

et al. 2018

Preprint

View full text Add to dashboard Cite

While radiotherapy is the first line of treatment for prostate cancer, androgen blockade therapies are demonstrating significant survival benefit as monotherapies. As androgen blockade can cause cell death by apoptosis, it is likely that androgen blockade will potentiate the cytotoxic activities of radiotherapy. Here we tested the potential synergistic effects of these two treatments over two human metastatic prostate cancer cells by real time growth monitoring (RTCA), androgen-sensitive LNCaP cells and androgen-resistant PC-3. Both cell lines were highly resistant to high doses of radiotherapy. A pre-treatment of LNCaP cells with IC50 concentrations of enzalutamide significantly sensitized them to radiotherapy through enhanced apoptosis. In contrast, enzalutamide resistant PC-3 cells were not sensitized to radiotherapy by androgen blockade. These results provide evidence that the enzalutamide/radiotherapy combination could maximize therapeutic responses in patients with enzalutamide-sensitive prostate cancer.

show abstract

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Cited by 96 publications

References 20 publications

Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer

Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

Radiopotentiation of Enzalutamide Over Human Prostate Cancer Cells as Assessed by Real-Time Cell Monitoring

Contact Info

Product

Resources

About